m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00086)
Target Name CDR1 antisense RNA (CDR1-AS)
Synonyms
CDR1-AS; CDR1NAT; ciRS-7; CDR1as; CDR1 natural antisense transcript; circular RNA sponge for miR-7
    Click to Show/Hide
Gene Name CDR1-AS
Chromosomal Location Xq27.1
Family Antisense RNAs
Gene ID 103611090
HGNC ID
HGNC:48926
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CDR1-AS can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Target Regulation Up regulation
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Responsed Drug ML-210 Investigative
 Drug Info 
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
Melanoma [ICD-11: 2C30]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Responsed Disease Melanoma [ICD-11: 2C30]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug ML-210 Investigative
 Drug Info 
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
ML-210 [Investigative]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
ML162 [Investigative]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
RSL3 [Investigative]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
References
Ref 1 Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.